Consistent with a pathogenic function, TLR2 stimulation of regulatory T cells (Treg) from MS patients reduced Treg suppressive functions and promoted a shift toward an inflammatory TH17 response (9). This evidence concerns the gene TLR2 and myeloid sarcoma.